GTG’s GeneType identifies 79.5% of people tested at risk of serious disease

Genetic Technologies shared the power of the geneType test in identifying risk and improving the health of populations worldwide. Since the geneType Risk Assessment Tests became available, GTG has tested a statistically significant number of people in Australia and the US. These results have revealed a compelling statistic: 79.5% of individuals tested showed an elevated risk for at least one disease. GTG believes this is a significant finding driving increased surveillance and screening which will ultimately lead to early detection, early intervention and, ultimately, save lives. GeneType is revolutionizing healthcare with its pioneering, non-invasive Multi-Risk Test, designed to uncover hidden risks of common yet serious diseases. This state-of-the-art test identifies individuals at elevated risk for a range of cancers, including breast, ovarian, pancreatic, prostate, colorectal, and melanoma, as well as cardiovascular diseases and metabolic conditions like Type 2 diabetes.